Pharma
Lipid-based excipients and active pharmaceutical ingredients „Made in Germany“ – you can rely on us.
Decades of experience and expertise shape today`s quality of our specialties and drive new product developments and operational excellence.
As a result, our brand names are considered all over the globe as the benchmark in parenteral nutrition as well as topical, oral, rectal applications and animal health.
Quality, compliance, functionality and technical support are the cornerstones of the day-to-day cooperation with customers and partners.
Our dedication and strict commitment to highest product purity and safety are reflected every day in the effort of our employees and the pursuit of continuous improvement.
The repeated confirmation of our Good Manufacturing Practices (GMP) by the responsible competent German authority and the US-FDA acknowledge our intention to deliver quality leadership to the healthcare industry.
Brands with tradition
EXCELLENCE IN EXCIPIENTS AND APIs
Lipid-based excipients made in Germany, manufactured in our EU GMP-certified and US FDA-approved production facility
Downloads
Essentials for Capsules
Download PDF
Lipids for Solid Dosage Forms
Download PDF
Excipients
Download PDF
Product List
Download PDF
WITEPSOL®
Download PDF
Quality & Regulatory
Download PDF
Excipients for Veterinary Application
Download PDF
Lipid Solutions for Injectables
Download PDF
Engineered Lipid Excellence for Topical Applications
Download PDF
MIGLYOL® 812 N & IMWITOR® 742
Download PDF
Please consider the environment before printing documents.
From our blog
Decades of expertise in the field of application technology – The Product Development (PD) department of IOI Oleo GmbH
IOI Oleo GmbH is known for its high-quality oleochemical specialities and the technical advice it provides on the use of its products. Thanks to its diversity and longstanding reliability, the product portfolio is used in the pharmaceutical, care, nutrition and technical applications sectors. The R&PD team and its expertise in application development is therefore continuously growing, keeping pace with the demands of the market.
The R&D department of IOI Oleo GmbH supports you – from the idea to the first product
As a leading company in the field of speciality lipids and pharmaceutical oleochemicals, IOI Oleo GmbH develops innovative and sustainable processes, products and formulations at its research centre in Witten.
Trust and transparency – IMWITOR® 742 now with CEP
Product lifecycle management (PLM) for pharmaceuticals ties up considerable capacities in the quality and regulatory departments over the entire lifecycle of the marketing authorisation. Efficient management of information relevant for the authorisation of newly developed, reformulated and generic medicinal products is therefore a significant success factor. In particular, change notifications for the active ingredients and excipients used can cause unforeseeable follow-up costs that are difficult to offset against the most competitive material prices.
Our debut as an exhibitor at CPHI China
In recent years, we have strategically strengthened our presence in the future-oriented Asian market: we have entered into new distribution partnerships and participated in numerous trade fairs. Together with our Chinese partner Beijing Fengli, we are now exhibiting at CPHI 2024 in Shanghai, emphasising our commitment to this dynamic and exciting region. Four experts from the Pharma business unit will be presenting IOI Oleo GmbH and our high-quality and proven portfolio. First and foremost, our highlights IMWITOR® 742 and MIGLYOL® 812 N Excipient, for which we recently completed the Chinese Pharmacopoeia (ChP) registration.
Core competence innovation: The R&D department of IOI Oleo GmbH
IOI Oleo GmbH is known for its high-quality oleochemical specialties and is regarded as a benchmark in many areas. To achieve and maintain this status, continuous work on existing products and innovations is required, as market requirements are changing rapidly. For this reason, we have built up a 14-strong R&D team and equipped it with the latest technology in order to be able to react proactively to trends and customer requirements.
Quality & continuity – The importance of consistently high quality of excipients and raw materials
We warmly invite you to visit our booth 29 in the exhibition area of the Austria Center Vienna from March 18 to 21, 2024 and talk directly to our team of experts from R&D, Regulatory and Galenics.
Regulatory innovations – Milestones for the Chinese market – IMWITOR® 742, MIGYLOL® 810 N & MIGLYOL® 812 N
The filing of two further dossiers with the Chinese NMPA* represents an outstanding milestone for customers in the Chinese market. From now on, manufacturers and exporters of finished pharmaceutical products can refer to these dossiers in their application documents. Our Regulatory Affairs department will issue your "Letter of Access" on request.
CEP 2.0 completely new? Effects on the quality and layout of the certificate
The high quality that we strive for in our portfolio is also reflected in our service. One aspect of this service is to make the usage of our excipients as simple and safe as possible; hence, we have selected products certified by the "European Directorate for the Quality of Medicines & HealthCare" (EDQM). The recent renewal of the certification system brings with it a number of improvements and changes.
Polymorphism in Lipids: Influence and Control in Pharmaceutical Applications
Polymorphism is a fundamental phenomenon observed in lipid materials, encompassing a diverse group of biomolecules such as fats, oils, and phospholipids. This phenomenon refers to the ability of lipids to exist in multiple structurally distinct states of crystallinity. Polymorphism in lipid materials has significant implications, e.g. in pharmaceutical and industrial applications. Controlling lipid polymorphism can be of paramount importance in the development of lipid-based drug delivery systems.